Ashton Thomas Private Wealth LLC Purchases Shares of 221 Moderna, Inc. (NASDAQ:MRNA)

Ashton Thomas Private Wealth LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 221 shares of the company’s stock, valued at approximately $26,000.

Other large investors have also recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Moderna during the 4th quarter valued at $347,565,000. Dynamic Technology Lab Private Ltd acquired a new stake in Moderna in the fourth quarter worth about $200,000. Sachetta LLC purchased a new stake in shares of Moderna during the fourth quarter worth about $56,000. D.A. Davidson & CO. increased its holdings in shares of Moderna by 227.3% during the fourth quarter. D.A. Davidson & CO. now owns 33,101 shares of the company’s stock valued at $3,292,000 after acquiring an additional 22,988 shares in the last quarter. Finally, Corient Private Wealth LLC raised its position in shares of Moderna by 13.7% in the 4th quarter. Corient Private Wealth LLC now owns 23,682 shares of the company’s stock valued at $2,355,000 after purchasing an additional 2,855 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 689 shares of the stock in a transaction on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 689 shares of Moderna stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the sale, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,158 shares of company stock valued at $11,167,312. 15.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

MRNA has been the topic of a number of recent analyst reports. Piper Sandler cut their price target on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. TD Cowen cut their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. The Goldman Sachs Group reduced their target price on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday. Bank of America dropped their price target on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research note on Friday, September 13th. Finally, Evercore ISI restated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $100.44.

Moderna Price Performance

NASDAQ:MRNA opened at $71.99 on Wednesday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The stock’s 50-day moving average price is $93.23 and its 200-day moving average price is $111.56. The stock has a market capitalization of $27.59 billion, a PE ratio of -4.59 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same period last year, the company earned ($3.62) earnings per share. As a group, equities analysts expect that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.